ClinicalTrials.gg
Status unknownNCT05498857Updated Aug 12, 2022

Intramuscular Ephedrine in the Prevention of Hypotension in Patients Undergoing Spinal Anesthesia

A Phase 4 interventional study of Intramuscular ephedrine and Placebo in Ephedrine, Intramuscular and Hypotension, sponsored by Hospital de Base. Status unknown at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-12.

Sponsored by Hospital de Base · Phase 4, Interventional, and Prevention

How we know

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing ephedrine in Hypotension — 4 open to participants now, 4 under way, none of them phase 3. Ephedrine · Hypotension.

Planned enrollment
2nd of 22
202 · median 120
Started
2022
with 1 other
Phase 4
11 of 22
2 open now
Registered
15th of 22
by date
Lead sponsor
1 of 22
Hospital de Base

Among the 22 studies testing ephedrine in Hypotension, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2022, is one of 11 in phase 4, and was the 15th registered.

Hypotension

892 studies on the registry are indexed under Hypotension; 199 are open to participants now.

Browse Hypotension studies →

Open to participants now

4 of the 22 studies testing ephedrine in Hypotension are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About ephedrine

Ephedrine: first FDA approval 2016 (AKOVAZ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 114 Hypotension studies recruiting now, 53 (46%) set no upper age limit and 36 (32%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing ephedrine in Hypotension, or all of them as a file.
02

Study summary

Subarachnoid anesthesia is an alternative and usually the first choice for many surgical procedures. It is a simple and safe procedure, however it can present complications such as hypotension and bradycardia. In this sense, ephedrine, an alpha and beta agonist agent, commonly used as rescue therapy for these events, is also potentially useful for prophylaxis of this unwanted effect and for less hemodynamic variation when preventively administered via the intramuscular route. Two groups will be divided: intramuscular ephedrine (0.5 mg/kg) and placebo. The variables analyzed and compared will be the incidence of hypotension and bradycardia, variation in mean and systolic blood pressure, heart rate, in addition to side effects. The main objective is to verify if the use of intramuscular ephedrine prior to spinal block is able to reduce the incidence of hypotension.

Read the detailed description

Subarachnoid or spinal anesthesia is an alternative and usually the first choice for many surgical procedures of the lower limbs, perineum and lower abdomen. It is a simple and safe procedure, however it can present complications such as hypotension and bradycardia. The incidence of hypotension and bradycardia is approximately 30 and 10%, respectively, during spinal anesthesia, however, the incidence of hypotension can be as high as 50 to 60% in obstetric patients.

In this sense, it is common for ephedrine, an agent with beta and alpha agonist action, to be the medication of first choice for rescuing hypotension and bradycardia after subarachnoid block, with part of its action happening by a direct mechanism and part by stimulus and indirect release. of endogenous catecholamines stored in the adrenal.

It is known that intramuscular administration has slower absorption and lower bioavailability of the drug compared to intravenous administration. Therefore, we have in our favor: a later serum peak, coinciding with the establishment of sympathetic block after spinal anesthesia, as well as more insidious effects, with less tendency to peaks and valleys and greater hemodynamic stability when compared to therapy alone. intravenous rescue. To assess this response, the main objective of the present study is to verify the hypothesis that the previous administration of ephedrine by intramuscular route reduces the incidence of hypotension induced by spinal anesthesia.

The proposal is a prospective, randomized, double-blind, placebo-controlled study in surgical procedures. Examiners responsible for evaluating patients will not have access to the agents used. Patients will be randomized through a list generated by lottery. The examiner responsible for opening the envelope, will perform the drawing, include the patient in one of the groups, write down his/her data in the random list, prepare the syringe with the medication, and deliver it to the operating room so that the following examiners will not be aware of the administered drug.

Patients will receive standard monitoring, venoclysis, intravenous midazolam as pre-anesthetic medication. Then, the study drug will be administered (ephedrine 0.3mg/kg intramuscularly or placebo). All patients received spinal anesthesia with hyperbaric bupivacaine and opioid adjuvants at the discretion of the anesthesiologist, except clonidine.

The evolution of vital signs such as systolic and mean blood pressure, heart rate, height of sensory block, incidence of adverse events such as bradycardia, tachycardia, hypertension or hypotension, nausea, vomiting, consumption of vasopressors and antiemetics will be evaluated.

03

Conditions studied

  • Ephedrine
  • Intramuscular
  • Hypotension
  • Spinal Anesthesia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over 18 years old, electively scaled for surgery requiring neuraxial block, with programming of spinal anesthesia.
  • Physical State 1, 2 or 3 of the American Society of Anesthesiology (ASA)

Exclusion criteria

Exclusion Criteria:

  • Patients taking prophylactic or therapeutic anticoagulation, except respecting the allowed range;
  • Patients with atrioventricular block
  • Patients with cardiac arrhythmias
  • Patients with heart failure;
  • Patients with renal disease
  • Patients with liver disease
  • Patient carrying or suspecting any type of systemic infection or located in a puncture site;
  • Patients who refuse to participate in the study after presenting the free and form;
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
202 participants (estimated)

Study arms

  • Active comparator
    Ephedrine group

    Patients will receive intramuscular ephedrine 0,5 mg/kg before spinal anesthesia

    Drug: Intramuscular ephedrine · Drug: Placebo

  • Placebo comparator
    Placebo group

    Patients will receive intramuscular saline before spinal anesthesia

    Drug: Intramuscular ephedrine · Drug: Placebo

Interventions

  • DrugEphedrineStudies of EphedrineEphedrine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive prophylactic intramuscular ephedrine plus standard spinal anesthesia

  • DrugPlacebo

    Patients will receive prophylactic intramuscular saline plus standard spinal anesthesia

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events as hypotension

    Intraoperative hemodynamic stability analysis through the incidence of bradycardia, hypotension and consumed vasopressors

    Time frame: During surgery

07

Study locations

1 of 1 sites recruiting
  • Hospital de Base do Distrito Federal
    Brasília, DF 70330-150, Brazil
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Jul 2023, 12 months after the start.

Of 61 non-industry phase 4 interventional studies under Hypotension, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's planned 12 months is close to that.

Counting every sponsor, half of 62 studies reached it within 12 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2022
First posted
Aug 12, 2022
StartActual
Jul 15, 2022
Primary completionEst.
Jul 2023
CompletionEst.
Jul 2023
Last update
Aug 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05498857
Lead sponsor
Hospital de Base
Responsible party
Fabricio Tavares Mendonca (MD, MSc, PhD, Hospital de Base) — Principal investigator
First posted
Aug 12, 2022
Start date
Jul 15, 2022
Primary completion
Jul 2023 (estimated)
Completion
Jul 2023 (estimated)
Last update
Aug 12, 2022

Study contacts

Fabricio T Mendonca, MD, MSc, PhD
Contact
correiodofabricio@gmail.com
5561981882640
Fabricio T Mendonca, MD, MSc, PhD
principal investigator · Hospital de Base do Distrito Federal

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ephedrine

Start the discussion